ALK and lung carcinoma: Its successor, ceritinib, which overcame crizotinib resistance in a subset of lung cancers (15), showed moderate responses in preclinical ALK-driven neuroblastoma models (16); however, only 20% of patients demonstrated neuroblastoma tumor response, followed in many by subsequent progression, likely due to adaptive mechanisms of resistance (16, 17).